文献速递膀胱癌与上尿路尿路上皮癌

晚期尿路上皮癌患者恩诺单抗维多汀治疗结局相关的基因组生物标志物:UNITE研究数据分析

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
PubMed 文献 · Eur Urol Oncol · 2024-12-20

UNITE研究中170例接受恩诺单抗维多汀(EV)单药治疗的晚期尿路上皮癌患者,比较有无特定生物标志物组的客观缓解率、无进展生存和总生存。CDKN2A和CDKN2B改变与更短的无进展生存相关,高肿瘤突变负荷与更长总生存相关,TSC1改变与更高客观缓解率相关。

要点

  • CDKN2A改变患者中位无进展生存4.6个月 vs 6个月(p=0.024)。
  • CDKN2B改变患者中位无进展生存4.4个月 vs 6个月(p=0.008)。
  • 高肿瘤突变负荷患者中位总生存13.6个月 vs 8.3个月(p=0.014)。

核心结论

  • 这项多机构回顾性研究在晚期尿路上皮癌患者中识别出可能与EV单药治疗结局相关的潜在生物标志物,应进一步研究。

研究设计与样本

  • 多机构回顾性研究,纳入UNITE研究中170例接受EV单药治疗且有分子生物标志物数据的患者。
  • 采用未校正逻辑回归比较客观缓解率,采用对数秩检验和Cox比例风险模型比较无进展生存和总生存。
  • 另采用校正临床特征的多变量Cox比例风险模型评估分子生物标志物。

主要发现

  • 患者中位年龄70岁,78%为男性,65%为纯尿路上皮癌组织学。
  • CDKN2A改变患者中位无进展生存4.6个月 vs 无改变者6个月(p=0.024)。
  • CDKN2B改变患者中位无进展生存4.4个月 vs 无改变者6个月(p=0.008)。
  • 高肿瘤突变负荷患者中位总生存13.6个月 vs 低肿瘤突变负荷者8.3个月(p=0.014)。
  • TSC1改变患者客观缓解率87% vs 无改变者51%(p=0.018)。

临床怎么用

  • 作者指出这些发现不会影响当前临床实践,但应在未来研究中进一步探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in the UNITE study who received EV monotherapy and had molecular biomarker data available. Outcomes for groups with and without a particular biomarker were compared using logistic regression (unadjusted) for the objective response rate (ORR), and a log-rank test and Cox proportional-hazard models (CPHMs) for progression-free survival (PFS) and overall survival (OS) from EV initiation. Molecular biomarkers were also evaluated in separate multivariable analyses using CPHMs that accounted for clinical characteristics. Median patient age was 70 yr; 78% of the cohort were male and 65% had pure UC histology. Median PFS was shorter for patients with CDKN2A alterations (4.6 vs 6 mo; p = 0.024) and for patients with CDKN2B alterations (4.4 vs 6 mo; p = 0.008). Median OS was longer for patients with high tumor mutational burden (13.6 vs 8.3 mo; p = 0.014). ORR was higher for patients with TSC1 alterations (87% vs 51%; p = 0.018). In multivariable analyses, CDKN2A and CDKN2B alterations were associated with inferior median PFS. This multi-institutional retrospective study of patients with aUC identified potential biomarkers associated with EV monotherapy outcomes that should be further investigated. PATIENT SUMMARY: We investigated genetic changes in urinary tract tumors that might be associated with response to enfortumab vedotin (EV) treatment in patients with advanced disease. Survival after EV treatment was longer for tumors with a higher number of mutations than for tumors with fewer mutations. However, mutations in two genes (CDKN2A and CDKN2B) were associated with worse outcomes after EV treatment. These findings will not affect current clinical practice, but should be investigated further in future studies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Jindal T, Jiang C, Alhalabi O, et al. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol. 2024. PMID: 39709257. doi:10.1016/j.euo.2024.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。